Literature DB >> 7617530

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

G L Amidon1, H Lennernäs, V P Shah, J R Crison.   

Abstract

A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1995        PMID: 7617530     DOI: 10.1023/a:1016212804288

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Gastrointestinal absorption of griseofulvin. II. Influence of particle size in man.

Authors:  M KRAML; J DUBUC; R GAUDRY
Journal:  Antibiot Chemother (Northfield)       Date:  1962-04

2.  Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination.

Authors:  J H Kou; D Fleisher; G L Amidon
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

3.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

4.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

5.  Mixing-tank model for predicting dissolution rate control or oral absorption.

Authors:  J B Dressman; D Fleisher
Journal:  J Pharm Sci       Date:  1986-02       Impact factor: 3.534

6.  Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat.

Authors:  H Lennernäs; O Ahrenstedt; A L Ungell
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

7.  Physicochemical model for dose-dependent drug absorption.

Authors:  J B Dressman; D Fleisher; G L Amidon
Journal:  J Pharm Sci       Date:  1984-09       Impact factor: 3.534

8.  Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds.

Authors:  G L Amidon; P J Sinko; D Fleisher
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

9.  Predicting fraction dose absorbed in humans using a macroscopic mass balance approach.

Authors:  P J Sinko; G D Leesman; G L Amidon
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

10.  Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications.

Authors:  P J Sinko; G D Leesman; G L Amidon
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

View more
  680 in total

1.  Does the dose-solubility ratio affect the mean dissolution time of drugs?

Authors:  P Lánský; M Weiss
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts.

Authors:  A Kalampokis; P Argyrakis; P Macheras
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

3.  The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology.

Authors:  W L Chiou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

4.  Use of 1-methyl-pyrrolidone as a solubilizing agent for determining the uptake of poorly soluble drugs.

Authors:  A S Uch; U Hesse; J B Dressman
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

5.  pH-metric solubility. 2: correlation between the acid-base titration and the saturation shake-flask solubility-pH methods.

Authors:  A Avdeef; C M Berger; C Brownell
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

6.  Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.

Authors:  E Nicolaides; E Galia; C Efthymiopoulos; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

7.  Absorption potential and its variants.

Authors:  H Boxenbaum
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 8.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

9.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

10.  Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?

Authors:  H H Blume; B S Schug
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.